Reber Emilie, Messerli Markus, Stanga Zeno, Mühlebach Stefan
Department for Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Bern University Hospital and University of Bern, 3010 Bern, Switzerland.
Department of Pharmaceutical Sciences, Pharmaceutical Care Research Group, University of Basel, 4050 Basel, Switzerland.
J Clin Med. 2019 Nov 19;8(11):2017. doi: 10.3390/jcm8112017.
Artificial nutrition, including enteral (EN) and parenteral (PN) nutrition, is indicated whenever adequate oral nutrition fails to sufficiently supply the necessary nutrients to the body. It is a convenient, efficacious, safe, and well-tolerated form of clinical nutrition in the hospital and home setting. EN is administered via nasogastric tube or ostomies while PN usually requires a central venous access for administration, straight into the blood stream. The infused nutrients can then be taken up directly by the different organs. PN is targeted as a single daily portion formulated as an oil-in-water emulsion providing the necessary substrates for the catabolic and anabolic metabolism including macro- and micronutrients and fluids. PN has a complex pharmaceutical composition-all-in-one admixture-and its compounding or ready-to-use preparation. The use of PN is more challenging and more expensive compare to the use of EN, commercially available as ready-to-use formulations. EN and concomitant medication is highly challenging. Upon incorrect handling and administration, PN is associated with potentially severe or even fatal complications, mostly relating to the central venous access (e.g., catheter-related sepsis) or to a metabolic intolerance (e.g., hyperglycemia, refeeding syndrome) because of inappropriate administration. A correct order of admixing, correct dosing, and administration of the artificial is crucial for safety and efficacy; clinical and biochemical monitoring of the patient and treatment regimen adaption are necessary. The high number of reactive solutes allow only limited stability of a ready-to-use PN admixture. The potential for numerous incompatibilities and interactions renders PN admixtures generally unsuitable as drug vehicle. Laboratory compatibility and stability testing and pharmaceutical expertise are a prerequisite to define the PN composition including nutrients or even drugs admixed to define the appropriate and individualized nutrition and medication regimen. The aim of this narrative review is to present the actual state-of-the-art to deliver best quality artificial nutrition with special regard on pharmaceutical aspects such as instabilities, incompatibilities, and concomitant co-medication.
人工营养,包括肠内营养(EN)和肠外营养(PN),在经口摄入的营养不能充分满足身体对必需营养素的需求时使用。在医院和家庭环境中,它是一种方便、有效、安全且耐受性良好的临床营养形式。肠内营养通过鼻胃管或造口给药,而肠外营养通常需要中心静脉通路将营养物质直接输入血流,使不同器官能够直接摄取输入的营养物质。肠外营养通常作为一日量的水包油乳剂,为分解代谢和合成代谢提供必要的底物,包括大量营养素、微量营养素和液体。肠外营养具有复杂的药物成分——全合一混合液——及其配制或即用型制剂。与现成可用的肠内营养制剂相比,肠外营养的使用更具挑战性且成本更高。肠内营养与同时用药也极具挑战性。如果处理和给药不当,肠外营养会引发潜在的严重甚至致命并发症,主要与中心静脉通路有关(如导管相关败血症)或代谢不耐受(如高血糖、再喂养综合征)。正确的混合顺序、正确的剂量和人工营养的给药对于安全性和有效性至关重要;对患者进行临床和生化监测以及调整治疗方案是必要的。即用型肠外营养混合液中大量的活性溶质使其稳定性有限。众多不相容性和相互作用的可能性使肠外营养混合液通常不适合作为药物载体。实验室相容性和稳定性测试以及药学专业知识是确定肠外营养成分(包括添加的营养素甚至药物)以制定合适的个体化营养和用药方案的先决条件。本叙述性综述的目的是介绍当前的最新技术,以提供高质量的人工营养,特别关注药物方面的问题,如不稳定性、不相容性和同时使用的联合用药。